US nod for Lynparza in HRD-positive advanced ovarian cancer

11th May 2020 Uncategorised 0

Lynparza has been cleared for use as a first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

More: US nod for Lynparza in HRD-positive advanced ovarian cancer
Source: News